Maximilian Seib
YOU?
Author Swipe
View article: Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell Engagers
Prognostic Value of Inflammation-Based Scores in R/R LBCL Patients Treated with CD3xCD20 Bispecific T-Cell Engagers Open
T-cell-redirecting bispecific antibodies (bsABs) offer a novel therapeutic approach for relapsed/refractory large B-cell lymphoma (r/r LBCL). However, predictive biomarkers are needed to identify patients most likely to respond. As both bs…
View article: Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma
Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed/refractory large B-cell lymphoma Open
Patients with large B-cell lymphoma (LBCL) who experience relapsed disease after CD19-directed chimeric antigen receptor (CAR) T-cell (CAR-T) therapy have a poor prognosis. Bispecific antibodies (BsAbs) induce complete remissions in ∼35% o…
View article: Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma
Time of CAR-T Failure Is a Strong Predictor of Outcome for Bispecific Antibody Therapy in Relapsed/Refractory Large B-Cell Lymphoma Open
Introduction Patients (pts) with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after CD19 chimeric antigen receptor (CAR)-T cell therapy are challenging to treat. CD20xCD3 T-cell-engaging bispecific antibodies (BsAbs) have emer…
View article: Multiple myeloma in the young: insights on prognosis, clinical features and treatment outcome derived from nationwide German registry data and a nested multicenter sample
Multiple myeloma in the young: insights on prognosis, clinical features and treatment outcome derived from nationwide German registry data and a nested multicenter sample Open
Not available.